Experience with imatinib mesylate in children with Ph+ chronic myelogenous leukemia

被引：0
|
作者：
Kapoor, Gauri [1 ]
Abedin, Sarfrazu [1 ]
Garg, Pravesh [1 ]
Tyagi, Vinod [1 ]
Khullar, Paras [1 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Delhi, India
来源：
PEDIATRIC BLOOD & CANCER | 2007年 / 49卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：528 / 528
页数：1
相关论文
共 50 条
  • [31] Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate
    Anthony, Navin
    Shanks, James
    Terebelo, Howard
    LEUKEMIA RESEARCH, 2010, 34 (09) : 1250 - 1251
  • [32] Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate
    Takeyoshi Itsukuma
    Hideki Ishikawa
    Mahito Misawa
    Shunro Kai
    Yoshihiro Fujimori
    Kazuhiko Nakagawa
    Seiichi Hirota
    Ayako Sugihara
    Nobuyuki Terada
    Hiroshi Hara
    Journal of Gastroenterology, 2007, 42 : 402 - 405
  • [33] Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate
    Itsukuma, Takeyoshi
    Ishikawa, Hideki
    Misawa, Mahito
    Kai, Shunro
    Fujimori, Yoshihiro
    Nakagawa, Kazuhiko
    Hirota, Seiichi
    Sugihara, Ayako
    Terada, Nobuyuki
    Hara, Hiroshi
    JOURNAL OF GASTROENTEROLOGY, 2007, 42 (05) : 402 - 405
  • [34] Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia
    Christoforidis, JB
    DeAngelo, DJ
    D'Amico, DJ
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 135 (03) : 398 - 400
  • [35] Evaluation of the effectiveness of imatinib on children with chronic myelogenous Leukemia
    Cheng, Yunzhou
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 : 294 - 294
  • [36] Adverse effects of imatinib in children with chronic myelogenous leukemia
    Choeyprasert, Worawut
    Yansomdet, Thitinun
    Natesirinilkul, Rungrote
    Wejaphikul, Karn
    Charoenkwan, Pimlak
    PEDIATRICS INTERNATIONAL, 2017, 59 (03) : 286 - 292
  • [37] Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience
    Braziel, RM
    Launder, TM
    Druker, BJ
    Olson, SB
    Magenis, RE
    Mauro, MJ
    Sawyers, CL
    Paquette, RL
    O'Dwyer, ME
    BLOOD, 2002, 100 (02) : 435 - 441
  • [38] A PHASE I/II STUDY OF NILOTINIB IN JAPANESE PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) OR RELAPSED/REFRACTORY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Usuki, K.
    Urabe, A.
    Tojo, A.
    Maeda, Y.
    Kobayashi, Y.
    Jinnai, I.
    Ohyashiki, K.
    Nishimura, M.
    Kawaguchi, T.
    Tanaka, H.
    Miyamura, K.
    Miyazaki, Y.
    Hughes, T.
    Branford, S.
    Okamoto, S.
    Ishikawa, J.
    Okada, M.
    Usui, N.
    Amagasaki, T.
    Natori, H.
    Naoe, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 433 - 434
  • [39] The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
    Sneed, TB
    Kantarjian, HM
    Talpaz, M
    O'Brien, S
    Rios, MB
    Bekele, BN
    Zhou, M
    Resta, D
    Wierda, W
    Faderl, S
    Giles, F
    Cortes, JE
    CANCER, 2004, 100 (01) : 116 - 121
  • [40] Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
    Kantarjian, HM
    Bueso-Ramos, CE
    Talpaz, M
    O'Brien, S
    Giles, F
    Faderl, S
    Wierda, W
    Rios, MB
    Shan, JQ
    Cortes, J
    CANCER, 2005, 104 (04) : 777 - 780
12345